{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:19:53Z","timestamp":1783653593190,"version":"3.55.0"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000},"content-version":"vor","delay-in-days":264,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Tarsus Pharmaceuticals"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>\n                    <jats:italic>Purpose<\/jats:italic>\n                    . Evaluate safety and efficacy of topical lotilaner ophthalmic solution, 0.25% for the treatment of\n                    <jats:italic>Demodex<\/jats:italic>\n                    blepharitis.\n                    <jats:italic>Patients and Methods<\/jats:italic>\n                    . 15 patients with\n                    <jats:italic>Demodex<\/jats:italic>\n                    blepharitis, defined as &gt;10 collarettes on the upper lid, lid margin erythema, and\n                    <jats:italic>Demodex<\/jats:italic>\n                    density of \u22651.5 mites\/lash on microscopy, were treated\n                    <jats:italic>bid<\/jats:italic>\n                    for 28 days with lotilaner ophthalmic solution, 0.25%. Contact lens wear, artificial eyelashes, and lid structural abnormalities were among the exclusion criteria. No other antibacterial, antiparasitic, or anti\u2010inflammatory treatment or lid hygiene products were permitted. Patients were assessed on Days 7, 14, 28, 60, and 90. Outcome measures were changes in collarette grade and mite density on Day 28. Adverse events and changes in intraocular pressure (IOP), corrected distance visual acuity (CDVA), and slit\u2010lamp biomicroscopy were assessed.\n                    <jats:italic>Results<\/jats:italic>\n                    . Mean collarette grade (upper lids) improved from 3.07\u2009\u00b1\u20090.21 to 0.79\u2009\u00b1\u20090.19 on Day 28; the change was statistically significant for both upper and lower lids from Day 14 on. Mean mite density per lash decreased from 2.28\u2009\u00b1\u20090.16 at baseline to 0.14\u2009\u00b1\u20090.05 at Day 28 (\n                    <jats:italic>p<\/jats:italic>\n                    &lt; 0.0001). Mite eradication (0 mites) was documented in 57.1% of eyes. The effects were durable through Day 90. There were no adverse events and little to no change in CDVA or IOP. The drop was well tolerated, with no discontinuations due to ocular irritation.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    . Topical lotilaner ophthalmic solution, 0.25% for 4 weeks, showed promising efficacy for the treatment of\n                    <jats:italic>Demodex<\/jats:italic>\n                    blepharitis. This novel treatment appears to be safe and well tolerated. Randomized controlled studies are needed to confirm the results.\n                  <\/jats:p>","DOI":"10.1155\/2021\/3862684","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T16:51:53Z","timestamp":1632329513000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of\n                    <i>Demodex<\/i>\n                    Blepharitis: A Pilot Study"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6654-5191","authenticated-orcid":false,"given":"Roberto","family":"Gonzalez-Salinas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3453-3062","authenticated-orcid":false,"given":"Elizabeth","family":"Yeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Holdbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3233-0536","authenticated-orcid":false,"given":"Stephanie N.","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Massaro-Corredor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Corredor-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nallely","family":"Ramos-Betancourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Quiroz-Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"e_1_2_9_1_2","volume-title":"Preferred Practice Pattern Guidelines. Blepharitis","author":"American Academy of Ophthalmology Cornea\/External Disease Panel","year":"2018"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.3109\/09286586.2011.642052"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-018-0624-3"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/icu.0000000000000168"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/opto.s142708"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0000000000001361"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1963.01590210056008"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/aci.0b013e32833df9f4"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/8949683"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-0275"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftale.2015.03.010"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2017.10.012"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2005.072363"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1645\/18-46"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S198585"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013333.pub2"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1080\/10412905.1997.9700780"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-765x.2008.02334.x"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/ico.0000000000002506"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-017-2475-z"},{"key":"e_1_2_9_21_2","unstructured":"U.S. Food & Drug Administration. Fact sheet for pet owners and veterinarians about potential adverse events associated with isoxazoline flea and tick products https:\/\/www.fda.gov\/animal-veterinary\/animal-health-literacy\/fact-sheet-pet-owners-and-veterinarians-about-potential-adverse-events-associated-isoxazoline-flea."},{"key":"e_1_2_9_22_2","unstructured":"European Medicines Agency Credelio summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/credelio-epar-product-information_en.pdf."},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.11.131"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-017-2470-4"},{"key":"e_1_2_9_25_2","unstructured":"VehigeJ. G. BabaS. N. CruzV. S. HoldbrookM. andHomM. A new treatment strategy forDemodexinfestation using topic antiparasitic isoxazoline drugs: results of ex vivo testing Proceedings of the American Academy of Optometry Annual Meeting October 2019 Orlando FL USA."},{"key":"e_1_2_9_26_2","unstructured":"PerksD. AHC 2224920: 13 Week oral (gavage) administration toxicity study in the rat followed by a 4-week treatment-free period 2015 Covance Laboratories Ltd Princeton NJ USA Report no. 8275617."},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.12.1574"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.ico.0000244870.62384.79"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s144483"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/icl.0000000000000415"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2007.00341.x"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-019-2108-1"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713683.2018.1536217"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2011.26.9.1231"}],"container-title":["Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2021\/3862684","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/2021\/3862684","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2021\/3862684","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:09:22Z","timestamp":1783652962000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2021\/3862684"}},"subtitle":[],"editor":[{"given":"Sentaro","family":"Kusuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1155\/2021\/3862684"],"URL":"https:\/\/doi.org\/10.1155\/2021\/3862684","archive":["Portico"],"relation":{},"ISSN":["2090-004X","2090-0058"],"issn-type":[{"value":"2090-004X","type":"print"},{"value":"2090-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"2021-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"3862684"}}